Background: Cannabinoid type 1 receptor (CB1-R) is a key mediator in the control of food intake and is linked to obesity. Aim: To evaluate the relationship between CB1-R gene polymorphism and dietary macronutrient intake in elderly subjects. Methods: This study included 118 subjects (60 males, 58 females) from a population survey carried out in southern Italy in 1992–1993 who were older than 65 years and previously characterized for CB1-R polymorphism (75 with GG wild-type genotype, 41 with heterozygous polymorphic allele AG, and 2 with genotype AA). All subjects completed a validated semi-quantitative food frequency questionnaire. Statistical methods included multiple logistic regression to model macronutrient intake to genotype, controlling for potential confounders. Results: When controlled for age, gender, and body mass index, the intake of dietary cholesterol and saturated fats corrected for calories was inversely associated with the CB1-R 1359 G/A polymorphism, while the intake of starchy carbohydrates was directly associated with this polymorphism. Conclusion: In our unselected elderly population, the 1359 G/A polymorphism is linked with a specific macronutrient intake. This could be explained by the role of the cannabinoid system as a determinant of food intake and eating behavior.

Keywords:
Cannabinoid receptor, Nutrients, Gene polymorphism, Population study, Phenotype
1.
Engeli S: Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight. Handb Exp Pharmacol 2012;209:357–381.
2.
Pagotto U, Pasquali R: Endocannabinoids and energy metabolism. J Endocrinol Invest 2006;29:66–76.
3.
Di Marzo V, Matias I: Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005;8:585–589.
4.
Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R: The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006;23:73–100.
5.
Engeli S, Jana B, Mareike F, Kerstin G, Jurgen J, Sandor B: Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005;54:2838–2843.
6.
Ravinet TC, Delgorge C, Menet C, Arnone M, Soubrie P: CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004;28:640–648.
7.
Lazzari P, Sanna A, Mastinu A, Cabasino S, Manca I, Pani L: Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice. Behav Brain Res 2010;217:432–438.
8.
Leite CE, Mocelin CA, Petersen GO, Leal MB, Thiesen FV: Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity. Pharmacol Rep 2009;61:217–224.
9.
Harrold JA, Elliott JC, King PJ, Widdowson PS, Williams G: Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food? Brain Res 2002;952:232–238.
10.
Di Marzo V, Bifulco M, De Petrocellis L: The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004;3:771–784.
11.
Felder CC, Glass M: Cannabinoid receptors and their endogenous agonists. Ann Rev Pharmacol Toxicol 1998;38:179–200.
12.
Aberle J, Flitsch J, Alessia N, Mann O, Busch P, Peitsmeier P, et al: Genetic variation may influence obesity only under conditions of diet: analysis of three candidate genes. Mol Genet Metab 2008;95:188–191.
13.
Benzinou M, Chèvre JC, Ward KJ, Lecoeur C, Dina C, Lobbens S, et al: Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations. Hum Mol Genet 2008;17:1916–1921.
14.
Jaeger J, Mattevi V, Callegari-Jacques SD, Hutz MH: Cannabinoid type 1 receptor gene polymorphisms are associated with central obesity in a Southern Brazilian population. Dis Markers 2008;25:67–74.
15.
Peeters A, Beckers S, Mertens I, Van Hul W, Van Gaal L: The G1422A variant of the endocannabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men. Endocrine 2007;31:138–141.
16.
Russo P, Strazzullo P, Cappuccio F, Tregouet D, Lauria F, Loguercio M, et al: Genetic variations at the endocannabinoid type 1 receptor gene (CRN1) are associated with obesity phenotypes in men. J Clin Endocrinol Metab 2007;92:2382–2389.
17.
Gazzerro P, Caruso MG, Notarnicola M, Misciagna G, Guerra V, Laezza C, et al: Association between cannabinoid type 1 receptor polymorphism and body mass index in a southern Italian population. Int J Obes 2007;31:908–912.
18.
Arnone M, Maruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrie P, et al: Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1997;132:104–106.
19.
Simiand J, Keane M, Keane PE, Soubrie P: SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 1998;9:179–181.
20.
Foltin RW, Haney M: Effects of the cannabinoid antagonist SR141716 (rimonabant) and d-amphetamine on palatable food and food pellet intake in non-human primates. Pharmacol Biochem Behav 2007;86:766–773.
21.
Escartín-Pérez RE, Cendejas-Trejo NM, Cruz-Martínez AM, González-Hernández B, Mancilla-Díaz JM, Florán-Garduño B: Role of cannabinoid CB1 receptors on macronutrient selection and satiety in rats. Physiol Behav 2009;96:646–650.
22.
Fidanza F: Nutrizione Umana. Napoli, Idelson, 1984.
23.
Leoci C, Centonze S, Guerra V, Cisternino AM, Misciagna G: Reliability and validity of a semiquantitative food frequency questionnaire. G Ital Nutr Clin Prev 1993;2:58–59.
24.
Misciagna G, Centonze S, Leoci C, Guerra V, Cisternino AM, Ceo R, et al: Diet, physical activity, and gallstones: a population-based case-control study in southern Italy. Am J Clin Nutr 1999;69:120–126.
25.
Pierucci P, Misciagna G, Ventura MT, Inguaggiato R, Cisternino AM, Guerra VM, et al: Diet and myocardial infarction: a nested case-control study in a cohort of elderly subjects in a Mediterranean area of southern Italy. Nutr Metab Cardiovasc Dis 2012;22:727–733.
26.
Schimdt LG, Samochowiec J, Finckh U, Fiszer-Piosik E, Horodnicki JB, Rommelspacher H, et al: Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. Drug Alcohol Depend 2002;65:221–224.
27.
Heaney RP: Nutrient effects: discrepancy between data from controlled trials and observational studies. Bone 1997;21:469–471.
28.
Finkelstein DI, Reeves AK, Horne MK: An electron microscopic tracer study of the projections from entopeduncular nucleus to the ventrolateral nucleus of the rat. Neurosci Lett 1996;211:33–36.
29.
Pecina S, Berridge KC: Opioid sites in nucleus accumbens shell mediate eating and hedonic liking for food: map based on microinjection Fos plumes. Brain Res 2000;863:71–86.
30.
Harrold JA, Williams G, Widdowson PS: Early leptin response to a palatable diet predicts dietary obesity in rats: key role of melanocortin-4-receptors in the ventromedial hypothalamic nucleus. J Neurochem 2000;74:1224–1228.
31.
Di Marzo V, Berrendero F, Bisogno T, Gonzales S, Cavaliere P, Romero J, et al: Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents of the striatum of Δ9–tetrahydrocannabinol-tolerant rats. J Neurochem 2000;74:1627–1635.
32.
Mechoulam R, Ben-Shabat S, Hanus L, Liqumsky M, Kaminski NE, Schatz AR, et al: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50:83–90.
33.
Berger A, Crozier G, Bisogno T, Cavaliere P, Innis S, Di Marzo V: Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc Natl Acad Sci USA 2001;98:6402–6406.
34.
Matias I, Petrosino S, Racioppi A, Capasso R, Izzo AA, Di Marzo V: Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: effect of high fat diets. Mol Cell Endocrinol 2008;286(suppl 1):S66–S78.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.